Recently, everolimus, a small molecule mTOR inhibitor, has been approved in the treatment of non-functional metastatic neuroendocrine tumors of the lung or gastrointestinal tract based on the progression-free survival benefit seen in the RADIANT-4 trial (23). The gene discussed is MTOR; the disease is neuroendocrine neoplasm.